Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase II Study of ADX-2191 in Subjects With Retinitis Pigmentosa

NCT05392179 is registered in ClinicalTrials.gov with Aldeyra Therapeutics, Inc. as lead sponsor.

NCT NCT05392179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05392179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase II Study of ADX-2191 in Subjects With Retinitis Pigmentosa
Lead sponsor
Aldeyra Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 14, 2022
Completion date
June 23, 2023
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinitis pigmentosa